CN102603763A - 一种从威灵仙中提取木脂素类化合物的方法及应用 - Google Patents
一种从威灵仙中提取木脂素类化合物的方法及应用 Download PDFInfo
- Publication number
- CN102603763A CN102603763A CN2012100381413A CN201210038141A CN102603763A CN 102603763 A CN102603763 A CN 102603763A CN 2012100381413 A CN2012100381413 A CN 2012100381413A CN 201210038141 A CN201210038141 A CN 201210038141A CN 102603763 A CN102603763 A CN 102603763A
- Authority
- CN
- China
- Prior art keywords
- extracting
- radix clematidis
- compounds
- extract
- resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- -1 lignans compounds Chemical class 0.000 title abstract description 9
- 241000903946 Clematidis Species 0.000 title abstract description 6
- 229930013686 lignan Natural products 0.000 title abstract description 6
- 235000009408 lignans Nutrition 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 210000004185 liver Anatomy 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 230000008635 plant growth Effects 0.000 claims abstract description 5
- 239000011347 resin Substances 0.000 claims abstract description 5
- 229920005989 resin Polymers 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 238000004007 reversed phase HPLC Methods 0.000 claims abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 3
- 238000000638 solvent extraction Methods 0.000 claims abstract description 3
- 241000218158 Clematis Species 0.000 claims description 22
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 241000607479 Yersinia pestis Species 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 241000238631 Hexapoda Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 238000004440 column chromatography Methods 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000005374 membrane filtration Methods 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000004237 preparative chromatography Methods 0.000 abstract 1
- 230000000452 restraining effect Effects 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001256368 Clematis chinensis Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000260447 Clematis armandii Species 0.000 description 1
- UOONOYCRERCRDU-CKOVKGACSA-N Clemochinenoside B Natural products O(C)c1c2c(OC)cc(C(=O)OC[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](O3)Oc3c(OC)cc(C(=O)OC[C@@H]4[C@H](O)[C@H](O)[C@@H](O)[C@H](O4)O2)cc3)c1 UOONOYCRERCRDU-CKOVKGACSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- NEVMWOQJRSZYIC-UHFFFAOYSA-N clemochinenoside-A Natural products COC1=CC(C(OCC2OC(C(C(O)C2O)O)O2)=O)=CC(OC)=C1OC(C(C(O)C1O)O)OC1COC(=O)C1=CC(OC)=C2C(OC)=C1 NEVMWOQJRSZYIC-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种从威灵仙中提取木脂素类化合物的方法及应用。包括:(1)将威灵仙进行水煮;或采用有机溶剂提取;或采用乙醇水溶液提取;或采用甲醇水溶液提取;(2)提取物浓缩后,使用大孔吸附树脂、离子交换树脂、硅胶层析法、中压制备色谱、半制备或制备RP-HPLC法进行纯化。本发明研究发现植物威灵仙中富含结构多样的木脂素类化合物。该类化合物可通过树脂吸附、膜过滤、溶剂萃取、柱色谱、高效液相色谱分离等方法得到富集或者纯化。从威灵仙中提取得到的含木脂素类化合物的组分或者纯的化合物有抗肿瘤、抗炎、抗菌、抗虫、抗氧化、抗风湿、保肝、抑制植物生长等作用,在生物医药领域具有重要应用前景。
Description
技术领域
本发明涉及中草药威灵仙的提取分离方法及用途。
背景技术
威灵仙(Clematis chinensis Osbeck),属毛茛科植物。它性温,味辛、咸,有毒,具有祛风除湿、通络止痛的功效,且有镇静、抗菌、消炎、抗癌和利尿等作用,还能促进胆汁的分泌,因此在临床治疗上,威灵仙常被用于治疗痛风顽痹、肢体麻木、筋脉拘挛,减弱风湿痹痛、诸骨鲠咽,减少水肿、降血压和治疗外伤等。
据文献报道,威灵仙中含原白头翁素、白头翁素、白头翁内酯、甾醇、糖类、皂苷、氨基酸及生物碱、有机酸、蒽醌等物质。如:Kizu等在威灵仙中分离到三萜皂苷;Song等分离到2个不常见的大环糖苷clemochinenoside A和B。此外,从威灵仙的根部提取物中分离得到一系列三萜甙。威灵仙的低极性挥发油包含有有机酸、有机酸酯、苯丙素、倍半萜、酚类等主要成分。威灵仙总皂苷具有抗肿瘤及抗炎镇痛的作用,而且在抗免疫性炎症方面有较强活性。威灵仙中所发现的大多数皂苷的苷元均为齐墩果酸,其具有清热、消炎、抑菌、强心、利尿和抑制S180瘤株生成的作用。
我们对威灵仙的化学成分进行了系统的研究,发现在威灵仙中含有结构多样性的木脂素类化合物,其中松脂素(pinoresinol)含量较高。松脂素是植物里的一个重要活性成分,是植物实现自我保护的重要化学物质,该物质还具有抗真菌、抗虫、抗炎和抗氧化的作用。
木脂素是一类天然酚类化合物,其结构是两个苯丙素单元的二聚体。木脂素在有些植物中的含量并不高。木脂素的提取和分离目前还没有形成系统、规范的方法,尤其是缺乏适合于批量或者规模化制备的方法。木脂素也是一类很重要的生物活性物质,具有广泛的生物活性,如抗肿瘤、抗炎、抗菌、抗虫、抗氧化、抗风湿、保肝、抑制植物生长等。我们首次发现威灵仙中富含结构多样性的木脂素类活性化合物,因此,以威灵仙为药用原材料,研究与开发创新药物,前景广阔。而且,以木脂素类化合物的组成和含量分析可作为威灵仙药材质量检测和所制成的中成药质量控制的方法。
发明内容
本发明以植物威灵仙(Clematis chinensis)、或者是以威灵仙为药用原材料制备抗风湿等药物的残液、残渣中提取、富集或者纯化木脂素类化合物的工艺方法,以及它们在抗肿瘤、抗炎、抗菌、抗虫、抗氧化、保肝、抑制植物生长等药物领域的新用途。
一种从威灵仙中提取木脂素类化合物的方法,包括:
(1)将威灵仙进行水煮;
或采用有机溶剂提取;
或采用乙醇水溶液提取;
或采用甲醇水溶液提取;
(2)提取物浓缩后,使用大孔吸附树脂、离子交换树脂、硅胶层析法、中压制备色谱、半制备或制备RP-HPLC法进行纯化。纯的化合物的结构可以通过NMR、MS、IR、UV等波谱数据的综合解析确定。
上述有机溶剂优选为乙醇、甲醇、丁醇或乙酸乙酯。
上述提取方法可以辅以加热、超声或者微波,以提高提取效率。
从威灵仙中提取得到的木脂素类化合物主要含有如下结构特点:
(1) (2) (3) (4) (5)
(6)
以上结构的木脂素类化合物还可以与糖基结合形成糖苷类化合物。
富集或者纯化得到的木脂素类化合物在抗肿瘤、抗炎、抗菌、抗虫、抗氧化、抗风湿、保肝、抑制植物生长等药物研制领域有新用途。可与药学可以接受的辅料制成注射剂、片剂、丸剂、胶囊剂、溶液、悬浮剂和乳剂等剂型,研制成新型药物。
以木脂素类化合物的组成和含量分析可作为威灵仙药材质量检测和所制成的中成药质量控制的方法。
具体实施方式
下面结合实施例对本发明作进一步说明。
实施例1: 植物威灵仙(Clematis chinensis)中木脂素类化合物的提取与纯化
a. 取新鲜晒干的威灵仙,碾碎。用50%的乙醇回流1小时,提取3次,合并提取液。
b.低温旋转蒸发除去乙醇,残余水层用乙酸乙酯提取3次,合并乙酸乙酯提取液,低温旋转蒸发至干。
c. 乙酸乙酯提取物经硅胶柱层析分离,以石油醚-乙酸乙酯-甲醇梯度洗脱,收集石油醚-乙酸乙酯3:1(V/V)至石油醚-乙酸乙酯1:2(V/V)的组分,该收集组分主要含木脂素类化合物。
d. 含木脂素类化合物的组分,经反相C18制备型高效液相色谱分离,以甲醇-水70:30(V/V)可将各个木脂素类化合物得到有效分离、纯化。
e. 将得到的纯木脂素类化合物测定NMR、MS、IR、UV等,鉴定结构。
实施例2:
a. 威灵仙药材碾碎,加水煮沸1小时,连续水提3次。水提液过滤弃去残渣,收集清液。
b. 水提清液用D101树脂吸附。用水、水-乙醇9:1(V/V)、水-乙醇7:3(V/V)、水-乙醇5:5(V/V)、水-乙醇3:7(V/V)、水-乙醇1:9(V/V)、乙醇洗脱,收集70%~100%乙醇洗脱组分,该组分含有木脂素类化合物。
c. 含木脂素类化合物的组分用反相C18制备高效液相色谱分离,以乙腈-水60:40(V/V)恒流洗脱,可制备得到系列纯的木脂素类化合物。
d. 纯化得到的几种主要的木脂素化合物的结构和核磁共振(NMR)实验数据列于如下表1。
表1 几种主要化合物结构和核磁共振数据
表1 几种主要化合物结构和核磁共振数据(续)
Claims (4)
1.一种从威灵仙中提取木脂素类化合物的方法,其特征在于包括:
(1)将威灵仙进行水煮;
或采用有机溶剂提取;
或采用乙醇水溶液提取;
或采用甲醇水溶液提取;
(2)提取物浓缩后,使用大孔吸附树脂、离子交换树脂、硅胶层析法、中压制备色谱、半制备或制备RP-HPLC法进行纯化。
2.如权利要求1所述的方法,其特征在于,所述有机溶剂为乙醇、甲醇、丁醇或乙酸乙酯。
3.如权利要求1所述的方法,其特征在于,所述提取方法辅以加热、超声或者微波。
4.权利要求1所得提取物木脂素类化合物在制备抗肿瘤、抗炎、抗菌、抗虫、抗氧化、抗风湿、保肝或抑制植物生长药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100381413A CN102603763A (zh) | 2012-02-20 | 2012-02-20 | 一种从威灵仙中提取木脂素类化合物的方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100381413A CN102603763A (zh) | 2012-02-20 | 2012-02-20 | 一种从威灵仙中提取木脂素类化合物的方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102603763A true CN102603763A (zh) | 2012-07-25 |
Family
ID=46521592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100381413A Pending CN102603763A (zh) | 2012-02-20 | 2012-02-20 | 一种从威灵仙中提取木脂素类化合物的方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102603763A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440461A (zh) * | 2018-02-12 | 2018-08-24 | 淮阴工学院 | 威灵仙在分离制备5-羟甲基糠醛中的应用 |
CN116284200A (zh) * | 2023-01-12 | 2023-06-23 | 成都普思生物科技股份有限公司 | 一种提取分离自威灵仙的化合物及其制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003252775A (ja) * | 2002-02-26 | 2003-09-10 | Kyowa Hakko Kogyo Co Ltd | Nk細胞活性化剤 |
CN1724014A (zh) * | 2005-06-29 | 2006-01-25 | 中国药科大学 | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 |
CN101347521A (zh) * | 2007-07-20 | 2009-01-21 | 天津天士力制药股份有限公司 | 一种威灵仙的有效组分及其制备方法与用途 |
WO2010107150A1 (ko) * | 2009-03-20 | 2010-09-23 | (주)뉴메드 | 허혈성 뇌질환 예방 및 치료용 약학조성물 |
CN102327335A (zh) * | 2011-07-26 | 2012-01-25 | 苏州宝泽堂医药科技有限公司 | 一种从威灵仙中提取总皂苷的方法 |
-
2012
- 2012-02-20 CN CN2012100381413A patent/CN102603763A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003252775A (ja) * | 2002-02-26 | 2003-09-10 | Kyowa Hakko Kogyo Co Ltd | Nk細胞活性化剤 |
CN1724014A (zh) * | 2005-06-29 | 2006-01-25 | 中国药科大学 | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 |
CN101347521A (zh) * | 2007-07-20 | 2009-01-21 | 天津天士力制药股份有限公司 | 一种威灵仙的有效组分及其制备方法与用途 |
WO2010107150A1 (ko) * | 2009-03-20 | 2010-09-23 | (주)뉴메드 | 허혈성 뇌질환 예방 및 치료용 약학조성물 |
CN102327335A (zh) * | 2011-07-26 | 2012-01-25 | 苏州宝泽堂医药科技有限公司 | 一种从威灵仙中提取总皂苷的方法 |
Non-Patent Citations (7)
Title |
---|
BAO-PING SHAO: "Phenolics from Clematis chinensis", 《NATURAL PRODUCT LETTERS》 * |
QIANG FU,等: "Triterpene Saponins from Clematis chinensis and Their Potential Anti-inflammatory Activity", 《JOURNAL OF NATURAL PRODUCTS》 * |
SHE-PO SHI,等: "New Phenolic Glycosides from Clematis mandshurica", 《HELVETICA CHIMICA ACTA》 * |
YOSHIHIRO MIMAKI,等: "Triterpene Saponins from the Roots of Clematis chinensis", 《JOURNAL OF NATURAL PRODUCTS》 * |
何明,等: "威灵仙化学成分的研究", 《药学学报》 * |
吴依娜,等: "中药材威灵仙的化学成分和药理研究概述", 《中国医药导报》 * |
李颜,等: "威灵仙化学成分和药理作用研究进展", 《中国药房》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440461A (zh) * | 2018-02-12 | 2018-08-24 | 淮阴工学院 | 威灵仙在分离制备5-羟甲基糠醛中的应用 |
CN116284200A (zh) * | 2023-01-12 | 2023-06-23 | 成都普思生物科技股份有限公司 | 一种提取分离自威灵仙的化合物及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singhuber et al. | Aconitum in traditional Chinese medicine—a valuable drug or an unpredictable risk? | |
CN101279964B (zh) | 愈创木烷型倍半萜、其制备方法及其医药用途 | |
Setzer | The phytochemistry of Cherokee aromatic medicinal plants | |
CN101259159A (zh) | 一种骆驼刺总黄酮的制备方法及其应用 | |
Rehman et al. | Nardostachys chinensis Batalin: A review of traditional uses, phytochemistry, and pharmacology | |
Wang et al. | Traditional applications, phytochemistry, and pharmacological activities of eupatorium lindleyanum dc.: A comprehensive review | |
Khanavi et al. | Pharmacological and histological effects of Centaurea bruguierana ssp. belangerana on indomethacin-induced peptic ulcer in rats | |
CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
Kong et al. | The traditional herb Polygonum hydropiper from China: A comprehensive review on phytochemistry, pharmacological activities and applications | |
CN101890084A (zh) | 黑种草子总苷提取物及其制备方法和应用 | |
Tahir et al. | Traditional herbal medicine and its clinical relevance: a need to preserve the past for the future | |
Wu et al. | Preparation of paeoniflorin from the stems and leaves of Paeonia lactiflora Pall.‘Zhongjiang’through green efficient microwave-assisted extraction and subcritical water extraction | |
CN102688261A (zh) | 一种凤尾草提取物及其制备方法和用途 | |
Nkuété et al. | Evaluation of multiple functions of Polygonum genus compounds | |
CN102603763A (zh) | 一种从威灵仙中提取木脂素类化合物的方法及应用 | |
CN114907199B (zh) | 抗炎、止痒的蒲公英二萜类化合物、其制备方法及应用 | |
CN102362877B (zh) | 一种雾水葛提取物的应用 | |
CN104910172A (zh) | 五种二苯乙烯三聚体的制备方法及其应用 | |
CN108743657A (zh) | 一种川西獐牙菜中苷类成分的制备方法 | |
CN105646638B (zh) | 长梗冬青苷的制备方法 | |
CN101481398B (zh) | 一种从独一味中同时制备高纯度5-羟基-独一味素a苷和独一味素a苷提取物的方法 | |
Kumar et al. | Acute and chronic inflammation studies of Strobilanthes callosus leaves extract on rat model | |
CN113968869A (zh) | 愈创木烷倍半萜内酯类化合物Artemvulactone及其制备方法和应用 | |
CN102010457A (zh) | 一种竹节香附素a的制备方法 | |
CN102188502B (zh) | 一种具有抗肿瘤作用的黄三七总皂苷的提取方法及其组成 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120725 |